Biopharmaceutical company Cassava Sciences, along with founder Remi Barbier and former Senior Vice President of Neuroscience Lindsay Burns, PhD, will pay more than $40 million to settle allegations ...

The Wisconsin Department of Health Services has denied the sale of three nonprofit SSM Health nursing facilities to a New Jersey-based for-profit company, the Wisconsin State Journal reported Sept. 27 ...

Norfolk, Va.-based Sentara Health is cutting about 200 positions, with a majority of the cuts coming from its health plan division.

CEO Dr. Jawad Shah has grown Insight Health System from a small physician office into a multistate hospital system.

Rockledge, Fla.-based Health First will transfer ownership of its Health First Cancer Institute building to Titusville, Fla.-based Parrish Healthcare as part of the health systems' collaboration.

As hospitals across the Southeast continue to assess the damage and prepare for an influx of patients, the storms' death toll has climbed. As of mid-day Sept. 27, at least 22 deaths were reported ...

In January 2022, entrepreneur Mark Cuban launched online pharmacy Cost Plus Drugs, which priced 100 medications by their manufacturing fee, a 15% markup, and a shipping and handling fee. Now boasting ...

The FDA has approved Cobenfy capsules from Bristol-Myers Squibb for the oral treatment of schizophrenia in adults. The medication, formerly known as KarXT, is the first antipsychotic medication to ...

Monique Díaz, MD, will assume the role of vice president and regional chief medical information officer for CommonSpirit Health's California region, according to her LinkedIn.

A Challenger, Gray & Christmas report published Sept. 26 showed that 12 hospital CEOs left their roles in August, down from 16 reported in the same month last year. Those exits spanned the U.S., ...

Boston-based Dana-Farber Cancer Institute will lead 12 other health systems and academic institutions across the U.S. in a new cancer consortium aimed at addressing health equity and survival rates ...

The phase 3 Tempo-1 trial for tavapadon, a dopamine receptor partial agonist, demonstrated significant efficacy as a monotherapy in early Parkinson's disease. Patients receiving the drug at doses of 5 ...